Key Takeaway
Most adults lose 10-15% of their body weight on semaglutide over 68 weeks. Learn about clinical trial results, expected timelines, and factors that affect your individual weight loss.
Most adults lose approximately 10-15% of their body weight on semaglutide 2.4 mg (Wegovy) over 68 weeks. In the important STEP 1[1] clinical trial, participants lost an average of 14.9% of their body weight, which translated to roughly 33 pounds for the average participant in that study.
What the Clinical Trials Show
Semaglutide for weight management has been studied extensively across the STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial program. These trials provide the most reliable data on expected weight loss outcomes.
STEP 1: The Landmark Trial
The STEP 1 trial enrolled 1,961 adults[1] with obesity (BMI of 30+) or overweight (BMI of 27+) with at least one weight-related condition. All participants received lifestyle counseling in addition to either semaglutide 2.4 mg or placebo. Key results at 68 weeks:
- Average weight loss with semaglutide: 14.9% of body weight
- Average weight loss with placebo: 2.4% of body weight
- One-third of semaglutide participants lost 20% or more of their body weight
- Over 86% of participants lost at least 5% of their body weight
Results Across Other STEP Trials
The broader STEP program confirmed these findings across different populations:
- STEP 2[2] (patients with type 2 diabetes): Average weight loss of 9.6% at 68 weeks. Weight loss tends to be more modest in patients with diabetes[2].
- STEP 3[3] (intensive behavioral therapy added): Average weight loss of 16.0%, showing that combining semaglutide with structured lifestyle programs enhances results.
- STEP 4[4] (withdrawal study): Participants who continued semaglutide maintained their weight loss, while those switched to placebo regained about two-thirds of what they had lost.
- STEP 5[5] (2-year data): Average weight loss of 15.2% at 104 weeks[5], demonstrating that results are sustained with continued use.
Weight Loss Timeline
Weight loss with semaglutide follows a predictable pattern:
- Weeks 1-4 (2.5 mg dose): Minimal weight loss during the initial titration phase, typically 1-3 pounds.
- Weeks 5-16 (dose escalation from 0.5 mg to 1.7 mg): Weight loss accelerates as the dose increases. Most people see 3-5% of body weight lost by this point.
- Weeks 17-68 (maintenance dose of 2.4 mg): Steady weight loss continues, with the most significant results appearing between months 4 and 12.
- After 68 weeks: Weight loss typically plateaus, and the focus shifts to weight maintenance.
What That Looks Like in Pounds
To put the percentages in practical terms:
- A person starting at 200 pounds might expect to lose roughly 25-30 pounds
- A person starting at 250 pounds might expect to lose roughly 30-38 pounds
- A person starting at 300 pounds might expect to lose roughly 38-45 pounds
These are averages. Individual results vary widely based on several factors.
Factors That Affect Your Results
Several variables influence how much weight you'll lose on semaglutide:
- Starting weight: People with higher starting weights tend to lose more total pounds but may lose a similar percentage of body weight.
- Diet and exercise: Semaglutide works best when combined with a reduced-calorie diet and increased physical activity. Trial participants all received lifestyle counseling.
- Diabetes status: Patients with type 2 diabetes typically lose less weight on semaglutide (around 10% vs. 15%), likely due to metabolic differences.
- Dose tolerance: Some patients can't tolerate the full 2.4 mg dose due to side effects and stay on a lower dose, which generally produces less weight loss.
- Adherence: Consistent weekly injections and sustained lifestyle changes are important for optimal results.
- Genetics and metabolism: Individual biological variability means some people are stronger responders to GLP-1 therapy than others.
What to Consider
Clinical trial averages represent group-level data. Some individuals lose significantly more than 15%, while others lose less than 5%. About 14% of participants in STEP 1 did not achieve at least 5% weight loss. Setting realistic expectations with your physician helps avoid frustration and supports long-term success. For a complete cost breakdown, see our compare GLP-1 providers.
View data table
| Category | Mean Body Weight Loss (%) | Detail |
|---|---|---|
| Tirzepatide | 22 | ~22% body weight at 72 wks |
| Semaglutide | 15 | ~15% body weight at 68 wks |
| Liraglutide | 8 | ~8% body weight at 56 wks |
| Retatrutide | 24 | ~24% in Phase 2 trial |
Weight loss isn't linear. Plateaus are normal, and weekly fluctuations are expected. Measuring progress over months rather than weeks gives a more accurate picture. Your physician may track additional health markers, such as blood pressure, A1C, and waist circumference, to assess the full benefit of treatment.
Semaglutide is intended as a long-term therapy. Discontinuing the medication typically results in weight regain, so discussing a sustainable treatment plan with your provider is important.
Frequently Asked Questions
How long does it take for How Much Weight Will I to show results?
Most patients begin noticing effects within 4-8 weeks of starting treatment. Full results for weight management typically appear over 12-16 weeks with consistent use and lifestyle modifications.
Can I take How Much Weight Will I with other medications?
Drug interactions vary depending on the specific medications involved. Always disclose your full medication list to your prescribing provider. Some oral medications may need timing adjustments since GLP-1s can affect gastric emptying.
Do I need a prescription for How Much Weight Will I?
Yes, GLP-1 receptor agonists require a prescription from a licensed healthcare provider. You can obtain a prescription through an in-person visit or a telehealth consultation with a qualified provider.
Medical References
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. [PubMed | ClinicalTrials.gov | DOI]
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. [PubMed | ClinicalTrials.gov | DOI]
- Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021;325(14):1403-1413. [PubMed | ClinicalTrials.gov | DOI]
- Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA. 2021;325(14):1414-1425. [PubMed | ClinicalTrials.gov | DOI]
- Garvey WT, Batterham RL, Bhatt DL, et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nat Med. 2022;28(10):2083-2091. [PubMed | ClinicalTrials.gov | DOI]
Start Your Semaglutide process with FormBlends
FormBlends connects you with licensed physicians who specialize in GLP-1 therapy for weight management. Your personalized treatment plan includes medical evaluation, proper dose titration, and ongoing support to maximize your results. Start your consultation today to see if semaglutide is right for you.